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Abstract
Background: To obtain information on cardiovascular morbidity, hypertension control, anemia and mineral
metabolism based on the analysis of the baseline characteristics of a large cohort of Spanish patients enrolled in
an ongoing prospective, observational, multicenter study of patients with stages 3 and 4 chronic kidney diseases
(CKD).
Methods: Multicenter study from Spanish government hospital-based Nephrology outpatient clinics involving 1129
patients with CKD stages 3 (n = 434) and 4 (n = 695) defined by GFR calculated by the MDRD formula. Additional
analysis was performed with GFR calculated using the CKD-EPI and Cockcroft-Gault formula.
Results: In the cohort as a whole, median age 70.9 years, morbidity from all cardiovascular disease (CVD) was very
high (39.1%). In CKD stage 4, CVD prevalence was higher than in stage 3 (42.2 vs 35.6% p < 0.024). Subdividing
stage 3 in 3a and 3b and after adjusting for age, CVD increased with declining GFR with the hierarchy (stage 3a <
stage 3b < stage 4) when calculated by CKD-EPI (31.8, 35.4, 42.1%, p 0.039) and Cockcroft-Gault formula (30.9, 35.6,
43.4%, p 0.010) and MDRD formula (32.5, 36.2, 42.2%,) but with the latter, it did not reach statistical significance (p
0.882). Hypertension was almost universal among those with stages 3 and 4 CKD (91.2% and 94.1%, respectively)
despite the use of more than 3 anti-hypertensive agents including widespread use of RAS blockers. Proteinuria (>
300 mg/day) was present in more than 60% of patients and there was no significant differences between stages 3
and 4 CKD (1.2 ± 1.8 and 1.3 ± 1.8 g/day, respectively). A majority of the patients had hemoglobin levels greater
than 11 g/dL (91.1 and 85.5% in stages 3 and 4 CKD respectively p < 0.001) while the use of erythropoiesis-
stimulating agents (ESA) was limited to 16 and 34.1% in stages 3 and 4 CKD respectively. Intact parathyroid
hormone (i-PTH) was elevated in stage 3 and stage 4 CKD patients (121 ± 99 and 166 ± 125 pg/mL p 0.001)
despite good control of calcium-phosphorus levels.
Conclusion: This study provides an overview of key clinical parameters in patients with CKD Stages 3 and 4 where
delivery or care was largely by nephrologists working in a network of hospital-based clinics of the Spanish National
Healthcare System.
Background
Although progress has been made in retarding the pro-
gression of chronic kidney disease (CKD) to end-stage
renal disease (ESRD), the prevalence of CKD as a whole
is rising in the United States and worldwide [1-5]. CKD
is associated with increased morbidity and mortality, a
negative impact on quality of life, progression to ESRD,
and represents an important burden for the healthcare
system [3,4]. In the CKD population, the risk of death
and cardiovascular events increases proportionally with
the decline of renal function, the risk of mortality
exceeding that seen in ESRD patients requiring renal
replacement therapy (RRT) in some studies [6-11].
According to data from the 1999-2004 National Health
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and Examination Survey (NHANES) [1], the crude CKD
prevalence estimate for adults’ aged 20 years or older in
the United States was 16.8%. Two large epidemiological
studies carried out in Spain showed a variable preva-
lence of CKD, ranging from 7.7% in the general popula-
tion [12] to 21.3% in a large cohort of patients attended
by primary care physicians [13].
The National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (K/DOQI) guidelines [14]
represent an important tool to evaluate patients with
different CKD stages. Because of the high prevalence of
co morbidities in CKD patients, achieving guideline-
based targets may be difficult. In fact, a cross-sectional
study reported that the treatment of modifiable cardio-
vascular risk factors in pre-dialysis CKD patients was
largely inadequate [14]. Data from large prospective
observational studies of the clinical course of patients
with CKD, particularly regarding morbidity and mortal-
ity and achievement of targets based on guidelines are
scarce [15-17]. We wanted to obtain information relative
to not only cardiovascular morbidity but also data rela-
tive to hypertension, anemia and mineral metabolism
from a large and contemporary Spanish cohort called
Morbimortalidad en Enfermedad REnal en pacieNtes
diAbéticos y no diabéticos (MERENA), which translates
into Morbimortality in CKD Stage 3-4 in Diabetic and
Non-diabetic Patients. MERENA is an ongoing prospec-
tive, observational, multicenter study aimed to assess
outcomes, such as renal disease progression, as well as
morbidity and mortality in a cohort of CKD stages 3-4,
with a planned follow-up of 5 years. Here we report the
baseline characteristics of this cohort, a total of 1,129
patients which provide a timely overview of the status of
CKD care delivery for Stages 3 and 4. For the purposes
of this report, we did not analyze potential differences
between diabetic and non-diabetic subjects, an objective
of the MERENA study; rather here we choose to direct
our focus towards the analysis of CKD by stages regard-
less of diabetes status.
Methods
Materials and methods
The MERENA study is a prospective, observational,
non-intervening, multi-center study designed by the
Spanish Study Group for Diabetic Nephropathy Grupo
Español de Estudio de la Nefropatía DIABética (GEEN-
DIAB) of the Spanish Society of Nephrology to charac-
terize the clinical management and outcomes after a 5-
year follow-up of two cohorts, diabetic and non-diabetic,
of patients with CKD stages 3-4 in a clinical practice
setting. Secondary objectives included the assessment of
cardiovascular comorbidities, blood pressure (BP), glyce-
mic and lipid control, use of antiplatelet therapy, man-
agement of anemia and CKD-MBD, and degree of
adherence to clinical practice guidelines by attending
nephrologists. The study was conducted at the outpati-
ent nephrology clinics of 55 hospitals evenly distributed
through the Spanish territory from the Spanish National
Healthcare system with free and equal access to all
citizens.
Study Population
All patients older than 18 years seen at participating
nephrology units with CKD stages 3 and 4 (using
MDRD-4 equation) according to K/DOQI guidelines
[14] from December 1, 2003 to April 30, 2004 were eli-
gible for inclusion in the study, whether they were inci-
dent (newly referred) or prevalent patients. Exclusion
criteria were as follows: age < 18 yr, CKD stages other
than 3 or 4, estimated time to progression to ESRD <
12 months, evidence of consumptive or disabling dis-
ease, malignancy, and active infection, inflammatory dis-
orders, or expected death within 12 months. All
participants gave written informed consent. The Ethics
Committee of the Hospital Universitario Bellvitge in
Barcelona approved the study protocol.
Assessment and Data Collection
All consecutive patients who met the inclusion criteria
of the study during the enrolment period were included.
Standardized data collection was ensured and conducted
by nephrologists using internet-based electronic case
report forms. Baseline data included: sex, age, weight,
height, body mass index (BMI), specialty of the physi-
cian who referred the patient to the nephrologist, K/
DOQI CKD stage, and associated co morbid conditions,
such as cardiovascular disease, diabetic status, hyperlipi-
demia, hypertension, or smoking status. The Charlson
co-morbidity index was calculated. Renal function was
estimated from the 4-variable Modification of Diet in
Renal Disease (MDRD) equation, CKD-EPI and Cock-
roft-Gault equations were also used.
All the participating centers used the same criteria to
define existing co morbidities and pathologies. These
had been defined in the study’s protocol, and together
with the recommendations for adherence to the clinical
practice guidelines, they had been published on the
researchers’ website.
Criteria for the diagnosis of coronary artery disease
included history of acute myocardial infarction, angina
or revascularization procedure. Cerebrovascular disease
included transient ischemic attack, stroke, and hemiple-
gia. Peripheral vascular disease included lower limb
intermittent claudication, revascularization (surgical or
percutaneous) or amputation. Cardiovascular disease
was defined as the history of at least one of the follow-
ing: ischemic heart disease, cerebrovascular disease and
peripheral vascular disease. Cardiac disease was defined
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as the history of one of the following: coronary artery
disease, myocardial infarction, congestive heart failure or
history of coronary revascularization. All diabetic
patients met the classification criteria established by the
American Diabetes Association. The diagnosis of dia-
betic nephropathy as a likely cause of CKD was made
by each investigator. This was generally based on the
presence of retinopathy, proteinuria diabetes mellitus
duration and all relevant clinical data. Hypertension was
considered if the patient had a BP ≥ 140/90 mm Hg or
need for antihypertensive drugs. Dyslipidemia included
total serum cholesterol > 5.2 mmol/L (200 mg/dL), or
triglycerides > 1.7 mmol/L (150 mg/dL), or high-density
lipoprotein (HDL) cholesterol < 1.0 mmol/L (40 mg/dL)
in males or 1.3 mmol/L (48 mg/dL) in females or low-
density lipoprotein (LDL) cholesterol > 2.6 mmol/L (100
mg/dL) or need of lipid-lowering drugs. Drugs pre-
scribed were also recorded. Anemia was defined accord-
ing to the K/DOQI 2006 Guidelines (serum hemoglobin
< 12 g/dL in females and 13.5 g/dL in males) and by the
2004 revised European Best Practice Guidelines (EBPG)
[18] (serum hemoglobin < 11.5 g/dL in females and 13.5
g/dL in males, and 12.0 g/dL in men aged > 70 years) or
use of erythropoiesis-stimulating agents (ESA) at any Hb
level.
Blood samples were analyzed at the respective hospital
laboratories of the participating centers. Complete blood
cell count, glycated hemoglobin (HbA1c), serum albu-
min and proteins, glucose, urea, creatinine, uric acid,
lipid profile, iron status, potassium, bicarbonate, cal-
cium, phosphorus, intact parathyroid hormone (i-PTH),
and 24-hour urinalysis (proteinuria, creatinine, and urea
nitrogen) were determined.
Missing data of the main variables at baseline are
noted in brackets as follows: MDRD equation (0%),
blood pressure (0%), triglycerides (3%), HDL-c (7.1%),
LDL-c (7.1%), HbA1c in diabetics (15%), hemoglobin
(0%), serum ferritin (7.4%), TSAT (31%), calcium (2%),
phosphorus (2%), and i-PTH (12.7%).
The referring physicians for the entire study included:
primary care physicians in 46.2% of cases, internal medi-
cine in 12%, endocrinology in 8.9%, urology in 6.9%, and
cardiology in 4.8%; the remaining patients were referred
by other specialists or after a hospital admission.
Each investigator was advised to adhere strictly to the
best practice guidelines and clinical recommendations
concerning: lifestyle practices, target BP, HbA1c in dia-
betics and lipid levels, management of anemia and bone
mineral disorders or use of antiplatelet agents. Recom-
mendations were uploaded onto the study’s researchers’
website. The STROBE statement checklist has been con-
sidered in data analysis and in the preparation of the
manuscript.
Statistical Analysis
Data are presented as numbers and percentages, or as
mean and standard deviation (SD). Differences between
diabetic and non-diabetic patients were assessed with
Student’s t test for quantitative variables and the chi-
square (c2) test for categorical variables. Statistical sig-
nificance was set at P < 0.05. Variables significantly
associated with cardiovascular disease were assessed
using binary logistic regression with forward stepwise
selection procedure. Categorical variables were also
adjusted by age when indicated. Analysis was performed
using SPSS version 15.0 for Windows.
Results
General characteristics
The mean age of the total cohort of 1,129 patients was
68 ± 13 years, (median age 70.9, range 19-94 years).
There were no significant differences in age between
CKD stages 3 and 4 (Table 1). There was a predomi-
nance of male subjects (64%) and the ethnicity was all
Caucasian. The subjects had been follow up in
Nephrology clinics for 24 months (24 ± 12) at the
point of entry into the study although it varied widely
within the cohort (range: 0-46 months). Only 70
patients (6.2%) were truly incidents (new patients). The
mean BMI was 28.4 kg/m2 and 31% of the patients
had BMI exceeding 30 kg/m2. BMI was significantly
higher in stage 4 than stage 3 CKD (Table 1) BMI in
male was lower than in female (28.0 ± 4.3 vs. 29.4 ±
5.8. p < 0.001).
There was also a high percentage of individuals with
history of diabetes mellitus (40.8%) (n = 461) (91.7%
type 2 diabetes mellitus and 8.2% type 1 diabetes melli-
tus), but diabetes as the cause of kidney disease was
only attributed to 26.1% of the total cohort based on
clinical assessment (See methods). The other causes of
CKD were: vascular disease (in 28% of patients), glomer-
ular disease (11.4%), interstitial renal disease (10.8%),
polycystic kidney disease (3.5%), and others (5.7%), and
the cause of the remaining 14.5% of cases were
unknown.
The mean creatinine of the cohort was 2.4 mg/dL.
The estimated creatinine clearance was 30 ± 8 ml/min
when calculated by the Cockcroft-Gault formula. The
MDRD estimated GFR was 28.8 ml/min/1.73 m2. Using
the MDRD formula for CKD staging, we found 38.5% of
subjects with stage 3 CKD and 61.5% of subjects with
stage 4 CKD.
The percentage of CKD stage 4 patients with BMI >
30 kg/m2 was significantly higher than in CKD stage 3
patients (36.1 vs. 24.5%) despite the percentage of indivi-
duals with diabetes mellitus being lower in CKD stage 4
as compared with CKD stage 3 (37.6 vs. 46.1%).
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Cardiovascular morbidity
History of cardiovascular disease (CVD) was reported in
39.1% of the cohort (Table 2). The percentage of
patients with history of congestive heart failure was
17.5% of the total cohort. History of coronary artery dis-
ease was present in 21.6% with a prevalence of history
of myocardial infarction in 11.1% of the patients. Cere-
brovascular disease was documented in 12.2% and per-
ipheral vascular disease in 19.7% of the patients. History
of current smoking was elicited in 9.6% of the patient
cohort while 36.2% of the patients were former smokers.
CKD stage 4 patients had a significantly higher per-
centage of CVD than CKD stage 3 patients (42.2 vs.
35.6%) (Table 2). The percentage of CVD was much
higher in older subjects (age ≥ 60yrs) than in younger
subjects (age < 60 yrs) (45.6 vs. 19.8%, p = 0.001).
The history of cardiac disease was also significantly
higher in Stage 4 CKD than in stage 3 CKD (38.5 vs.
31.3% p < 0.01). There was also a significantly higher
history of congestive heart failure (CHF) in stage 4 and
3 CKD patients (19.7% vs. 15.1%, p < 0.045) (Table 2).
There were no significant differences in coronary artery
disease, myocardial infarction, peripheral vascular dis-
ease and cerebrovascular disease between stage 4 CKD
and stage 3 CKD patients (table 2).
To better examine CVD as a function of estimated
GFR and given the wide rage of GFR in stage 3, we
used the staging of 3a and 3b for this analysis. After
adjusting for age, CVD increased with declining GFR
with the hierarchy (stage 3a < stage 3b < stage 4) when
calculated by CKD-EPI (31.8, 35.4, 42.1%, p 0.039) and
Cockcroft-Gault formula (30.9, 35.6, 43.4%, p 0.010) and
Table 1 General characteristics and renal parameters:
Characteristics Total
(n = 1129)
CKD Stage 3
(n = 434)
CKD Stage 4
(n = 695)
P value
Age (yr; mean ± SD]) [range] 68 ± 13 [19-94] 68 ± 13 [19-89] 67 ± 13 [19-94] 0.428
Male gender (%) 64.0 75.3 57.0 0.001
Female gender (%) 36.0 24.7 43.0 < 0.001
Previous follow-up (months) [range] 24 ± 12 [0-46] 25 ± 7 [0-46] 23 ± 4 [0-46] 0.004
BMI (kg/m2; mean ± SD) [range] 28.4 ± 4.9 [15.6-60] 27.8 ± 4.3 [15.6-60] 29.0 ± 5.2 [18.2-43] < 0.001
Patients with BMI > 30 kg/m2 (%) 31.7 24.5 36.1 0.001
Patients with BMI between 25-29.9 kg/m2 (%) 45.7 49.0 43.6 0.096
Patients with BMI < 25 kg/m2 (%) 22.7 26.4 20.3 0.018
Diabetes Mellitus (%) 40.8 46.1 37.6 0.003
Serum creatinine (mg/dL) [range] 2.4 ± 0.7 [1.3-5.7] 2.0 ± 0.5 [1.3-3.5] 2.7 ± 0.6 [1.7-5.7] 0.001
eGFR (MDRD) ml/min/1.73 m2 [range] 28 ± 8 [15-58] 33 ± 8 [30-58] 23 ± 5 [15-29] 0.001
Cockcroft-Gault creat. clear. ml/min [range] 30 ± 8 [12-62] 37 ± 7 [21-62] 23 ± 4 [12-4] 0.001
Table 2 Cardiovascular morbidity
Characteristics Total
(n = 1129)
CKD Stage 3
(n = 434)
CKD Stage 4
(n = 695)
P value
Cardiovascular disease (CVD) (%)a 39.1 35.6 42.2 0.024
Percentage of patients < 60years with CVD 19.8 19.2 20.1 NS
Percentage of patients > 60years with CVD 45.6 47.1 44.5 NS
Cardiac disease (%)b 35.1 31.3 38.5 0.012
Congestive heart failure (%) 17.5 15.1 19.7 0.039
Coronary artery disease (%) 21.6 20.7 22.4 0.362
Myocardial Infarction (%) 11.1 11.0 11.2 0.958
Cerebrovascular disease (%) 12.2 10.4 13.7 0.050
Peripheral vascular disease (%) 19.7 18.7 20.0 0.289
Current smoking (%) 9.6 10.5 8.8 0.410
Former smokers (%) 36.2 35.7 36.7 0.525
a cardiovascular disease defined as the history of at least one of the following: ischemic heart disease, cerebrovascular disease and peripheral vascular disease.
b cardiac disease defined as the history of one of the following: coronary artery disease, myocardial infarction, congestive heart failure or history of coronary
revascularization
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MDRD formula (32.5, 36.2, 42.2%,) but with the latter, it
did not reach statistical significance (p 0.882) (Figure 1).
After subdividing stage 3 CKD into stages 3a and 3b,
there were also significant differences in age adjusted car-
diac disease, congestive heart failure and cerebrovascular
disease but not peripheral vascular disease (Figure 2).
Blood pressure, proteinuria and use of anti-hypertensive
agents
A majority of subjects had history of hypertension
(92.7%) and there was no significant difference in the
prevalence of hypertension between CKD stages 3 and 4
(Table 3). The definition of hypertension included sub-
jects on antihypertensive treatment (See methods).
The percentage of patients with a systolic BP < 130
mm Hg and a diastolic BP < 80 mm Hg was 22.1% and
51.4%, respectively. Only 17.4% of the total cohort had
systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg
(Table 3).
For the cohort as a group, the mean systolic BP was
141 ± 19 mm Hg and mean diastolic BP was 76 ± 11
mm Hg. CKD Stage 3 and 4 patients had a mean systo-
lic BP which was not significantly different from each
other. The mean diastolic BP, however, was slightly but
significantly higher in stage 3 than stage 4 patients.
The percentage of patients on 3 or more anti-hyper-
tensive drugs for the total cohort was 47.7% and there
were no significant differences between stage 3 and 4
(Table 3). A slightly higher percentage of patients were
on 3 or more anti-hypertensive medications in stage 4
than stage 3 CKD but the difference was not significant.
The percentage of patients on angiotensin-converting
enzyme (ACE) inhibitors was 43.3% and on Angiotensin
II receptor blockers (ARB) was 44.8%. The patients on
combination therapy with both ACE inhibitors and ARB
were 10.8% of the total cohort.
There were a significantly lower percentage of subjects
on ACE inhibitors and ACE inhibitors combined with
ARBs in stage 4 than in stage 3 CKD patients (Table 3).
No significant differences were noted among the percen-
tage of patients on ARBs and combination therapy with
ACEI and ARBs between stages 3 and 4 CKD. A slightly
higher percentage of patients were on diuretics in stage
4 than stage 3. No significant differences were found in
the percentage of patients on calcium channel blockers,
 
Figure 1 Overall cardiovascular disease (CVD). An increase in
CVD is shown as GFR declines using MDRD formula, upper panel,
Cockcroft-Gault formula middle panel, and EPI-CKD formula lower
panel. The increase in CVD is statistically significant using the
Cockcroft-Gault, and EPI-CKD formula but not with MDRD formula.
Figure 2 Summary of cardiovascular morbidity types based on
staging of CKD (stages 3a, 3b, 4). A significant increase in cardiac
disease (CD), congestive heart failure (CHF) and cerebrovascular
disease is seen. The increase in Peripheral vascular disease ( PVD)
was not statistically significant.
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beta blockers and alpha blockers between both the
groups.
Hyperkalemia defined as potassium levels > 5.4 mEq/
dl was more frequently observed in stage 4 than in stage
3 CKD (Table 3).
Proteinuria (> 300 mg/day) was present in 62.8% of the
subjects with a mean of 1.2 ± 1.8 g/24 hrs) despite of the
widespread use of ACE-inhibitors and ARB drugs. The
mean protein excretion was not significantly different
between stages 3 and 4 CKD groups (1.2 ± 1.8 vs. 1.3 ±
1.8 g/24 hrs). The percentage of patients with proteinuria
however, was significantly higher in subjects with CKD
stage 4 than in CKD stage 3 (66.8 vs 56.6%, p = 0.001).
The plasma lipid levels are given in Table 4. There
were no significant differences in the LDL-cholesterol,
HDL-cholesterol and the triglyceride levels in CKD
stage 3 and 4 patients. The percentage of patients trea-
ted with statins was 54.7% and there were no differences
in stage 3 and stage 4 patients (Table 4). Only one third
of the patients had LDL-c below 100 mg/dl, and this
percentage was lower for LDL-c < 70 mg/dl (8.3%). The
percentage of patients treated with aspirin or other anti-
platelet agents was 46.2% and no differences were found
between stages 3 and 4 CKD patients.
Anemia parameters and use of ESA and iron
According to the K-DOQI and the European Best Prac-
tices Guidelines (EBPG), anemia was present in 51.3%
and 30.5% of the total subjects, respectively. The mean
hemoglobin for the cohort as a whole was 12.8 g/dL
and the majority of patients (87.8%) had hemoglobin
greater than 11 g/dL (Table 5). The percentage of
patients with severe anemia (hemoglobin < 9 g/dL) was
1.6% and the percentage of patients with hemoglobin
between 9 and 11 g/dL was 11.5%. About 25% of the
total cohort was receiving ESA and the mean hemoglo-
bin in this group while receiving this therapy was 12 ±
1.5 g/dL and the range was wide (Table 5). The mean
ferritin level was 150 ng/mL (range 5-1500) and the per-
centage of patients with transferrin saturation < 20%
was 26.3%. The percentage of patients on oral and IV
iron supplementation were 31.9% and 3.0%, respectively.
The mean hemoglobin was significantly lower in stage
4 when compared to stage 3 CKD patients (12.4 ± 1.6
vs. 13.2 ± 1.7 g/dL). The percentage of patients with
hemoglobin greater than 11 g/dL was significantly
higher in stage 3 than stage 4 CKD patients (91.1 vs
85.5% p < 0.001). Conversely, the percentage of patients
with hemoglobin < 9 g/dL was significantly lower in
stage 3 than stage 4 CKD patients (0.5 vs 2.3% p <
0.001). No significant differences were noted in the per-
centage of patients with hemoglobin between 9 and 11
g/dL between CKD stage 3 and 4 patients (Table 5).
A significantly higher proportion of CKD stage 4 sub-
jects were receiving ESA as compared to stage 3 CKD
(34.1% vs. 16%, respectively). No significant differences
Table 3 Blood pressure, proteinuria and use of anti hypertensive agents
Characteristics Total
(n = 1129)
CKD Stage 3 CKD Stage 4 P value
Hypertension (%) 92.7 91.2 94.1 0.06
Systolic BP < 130 mm Hg (%) 22.1 22.5 21.6 0.72
Diastolic BP < 80 mm Hg (%) 51.4 46.4 55.9 0.001
% of patients with BP < 130/80 mm Hg 17.4 19.4 16.3 0.18
% of patients with BP < 140/90 mm Hg 40.8 45.9 37.7 0.007
Systolic BP (mm Hg; mean ± SD) 141 ± 19 141 ± 19 142 ± 20 0.4
Diastolic BP (mm Hg; mean ± SD) 76 ± 11 78 ± 10 75 ± 11 0.001
Percentage of pts with proteinuria (> 300 mg/24 hrs) (%) 62.8 56.6 66.8 0.001
Proteinuria (g/24 h; mean [SD]) 1.2 ± 1.8 1.2 ± 1.8 1.3 ± 1.8 0.60
Angiotensin-converting enzyme (ACE) inhibitors (%) 43.3 46.9 40.0 0.02
Angiotensin II receptor blockers (ARB) (%) 44.8 47.7 42.2 0.06
Combined ACE and ARB (%) 10.8 12.1 9.6 0.18
Diuretics (%) 65.7 61.5 69.6 0.004
Calcium channel blockers (%) 45.7 45.8 45.6 0.94
Beta blockers (%) 21.1 22.5 19.8 0.25
Alpha blockers (%) 23.4 23.5 23.3 0.95
% of patients with 3 or more antihypertensive drugs 47.7 45.8 49.7 0.18
Mean serum potassium levels (mEq/dL; mean ± SD, [range]) 4.82 ± 0.60 [3-6.7] 4.71 ± 0.57 [3-6.4] 4.88 ± 0.61 [3.1-6.7] 0.001
% of patients with potassium levels > 5.4 mEq/dL 14.3 9.8 17.1 0.001
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were found in the mean hemoglobin between CKD stage
4 and 3 patients treated with ESA. The percentage of
patients receiving ESA with hemoglobin levels < 9 g/dL,
between 9-11 g/dL and > 11 g/dL were not significantly
different in stages 3 and 4 CKD (Table 5). No significant
differences were reported in the mean weekly dose of
rHu-EPO and Darbepoetin in both the CKD groups (data
not shown). No significant differences were noted among
the patients with transferrin levels < 20% in both the
groups. A significantly higher percentage of patients in
CKD stage 4 were receiving oral and IV iron supplemen-
tation when compared to stage 3 CKD patients (39.5% vs.
23.6% and 4.4% vs. 1.6%, respectively) (Table 5).
Figure 3 shows the distribution of anemia arbitrarily
defined as Hb levels < 11 as a function of declining
GFR. With declining GFR the % of patients with Hb <
11 g/dL increases progressively.
PTH and calcium-phosphorus parameters
The mean phosphorus level was 3.7 mg/dL, the mean
calcium-phosphorus product was 35 mg2/dL2 and the
mean intact PTH level was 145 pg/mL. The serum
phosphorus was significantly higher in stage 4 than
stage 3 CKD while the serum calcium was not signifi-
cantly different (Table 6). The Ca-P product was slightly
but significantly higher in stage 4 than stage 3. Intact
PTH was significantly higher in stage 4 than stage 3
(166 vs. 121 pg/mL, p = 0.001).
85.1% of the patients had phosphorus levels within the
K-DOQI target (Table 6) and 57.6% of the patients had
mean calcium values within the K-DOQI target. 98.6%
of the patients had the Ca-P product within the K-
DOQI target whereas only 24.4% of the patients had
mean intact PTH values within the K-DOQI target. The
composite target for all the four parameters as per the
Table 4 Lipids, statins and anti-platelet therapy
Characteristics Total
(n = 1129)
CKD Stage 3 CKD Stage 4 P value
Total cholesterol (mg/dL; mean ± SD [range]) 195 ± 42 [30-171] 193 ± 38 [93-313] 196 ± 43 [74-396] 0.27
LDL-cholesterol (mg/dL; mean ± SD [range]) 116 ± 37 [30-271] 116 ± 38 [39-217] 116 ± 36 [30-271] 0.94
HDL-cholesterol (mg/dL; mean ± SD [range]) 50 ± 14 [2-99] 49 ± 13 [20-99] 51 ± 14 [23-99] 0.15
Triglycerides (mg/dL; mean ± SD [range]) 147 ± 89 [40-900] 151 ± 92 [40-900] 143 ± 87 [40-860] 0.14
Patients treated with statins for cholesterol control (%) 54.7 56.2 53.2 0.30
Patients with LDL-c < 100 mg/dl (%) 34.8 32.9 36.0 0.32
Patients with LDL-c < 70 mg/dl (%) 8.3 7.6 8.8 0.52
Patients treated with aspirin or other anti-platelet agents (%) 46.2 45.3 47.11 0.52
Patients with serum albumin in normal range (%) 87.9 89.0 88.6 0.54
Serum albumin (g/dL) [range] 3.9 ± 0.4 [1.7-6] 3.9 ± 0.4 [1.7-6] 3.9 ± 0.4 [1.7-6] 0.79
Table 5 Anemia parameters and the use of ESA and iron
Characteristics Total
(n = 1129)
CKD Stage 3
(n = 434)
CKD Stage 4
(n = 695)
P
value
Anemia according to K-DOQI guidelines (%) 51.3 43.7 58.1 0.001
Anemia according to EBPG (%) 30.5 25.5 36.0 0.001
Hemoglobin (g/dL; mean ± SD [range]) 12.8 ± 1.6 [7.6-
18.7]
13.2 ± 1.7 [7.6-
18.7]
12.4 ± 1.6 [7.6-
16.9]
0.001
% of patients with Hemoglobin levels greater than 11 gm/dL 87.8 91.1 85.5 0.001
% of patients with Hemoglobin levels between 9 and 11 gm/dL 11.5 8.6 13.3 0.095
% of patients with Hemoglobin levels less than 9 gm/dL 1.6 0.5 2.3 0.001
Treatment with ESA* (%) 25.5 16.0 34.1 0.001
Mean hemoglobin levels in patients treated with ESA (g/dL; mean ± SD
[range])
12.0 ± 1.5 [7.0-
17.4]
12.3 ± 1.5 [9.3-
17.4]
12.0 ± 1.5 [7.0-
16.2]
0.15
Ferritin (ng/mL; mean ± SD [range]) 150 ± 47 [5-1500] 129 ± 117 [5-997] 169 ± 168 [5-
1500]
0.001
Iron (μg/dl; mean ± SD [range]) 70 ± 26 [6-230] 75 ± 28 [6-230] 67 ± 25 [9-197] 0.001
Transferrin saturation < 20% (%) 26.3 23.4 28.5 0.12
Treatment with oral Iron (%) 31.9 23.6 39.5 0.001
Treatment with intravenous Iron (%) 3.0 1.6 4.4 0.001
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K-DOQI guidelines was met in only 10.5% of the total
cohort and 12.2 and 9.0% for stages 3 and 4,
respectively.
The percentage of patients being treated with vitamin
D supplementation and phosphate binders were 15%
and 19.7%, respectively. A significantly higher percen-
tage of patients were on vitamin D and phosphate bin-
ders in stage 4 than in stage 3 CKD (Table 6).
Discussion
The MERENA study was designed as a prospective
observational multicenter study of morbidity and mor-
tality to characterize the delivery of care and outcomes
after a 5 year follow up of CKD stage 3 and 4 patients
under the care of nephrologists working in a network of
hospitals of the Spanish National Healthcare System.
Here we report the baseline characteristics of this cohort
that includes 1,129 patients and discuss the most rele-
vant differences between stage 3 and 4 CKD patients
not only in terms of cardiovascular morbidity but also
in the areas of control of hypertension and proteinuria,
anemia management and mineral metabolism.
Individuals with reduced GFR are at a high risk of car-
diovascular outcomes [6-11]. A recent study by Weiner
et al. [9] confirmed that reduced GFR below 60 ml/min
represents a risk factor for cardiovascular morbidity and
mortality. In our study, GFR was estimated by both
MDRD and Cockcroft-Gault formulas. Concordant with
the findings of Weiner et al [9], and previous findings
by others [6] our study found that reduced GFR below
59 ml/min, which includes CKD stages 3 and 4, was
associated with a high prevalence of cardiovascular dis-
ease. However, the differences in CVD prevalence
between stages 3 and 4 CKD were relatively small (35%
vs. 42% in stages 3 and 4, respectively). To further ana-
lyze the calculated GFR effect on CVD, stage 3 subjects
were subdivided into stage 3a and 3b. This analysis was
done using not only the MDRD formula, which was the
initial purpose of this study, but also using the Cock-
croft-Gault formula and the more recently described
EPI- CKD formula [19]. With all formulas CVD preva-
lence adjusted by age increases with declining GFR with
the hierarchy (stage 3a < stage 3b < stage 4) (Figure 1).
Of note, however, the change in CVD morbidity did not
reach statistical significance with the MDRD formula.
While the MDRD formula has been very useful to assess
the burden of CKD in epidemiologic studies [6], it is
Figure 3 Percentage of CKD stage 3 and 4 patients with
hemoglobin less than 11 as a function of GFR.
Table 6 PTH and calcium-phosphorus metabolism.
Characteristics Total
(n = 1129)
CKD Stage 3
(n = 434)
CKD Stage 4
(n = 695)
P value
Phosphorus (mg/dL; mean ± SD [range]) 3.7 ± 0.7
[1.7-6.7]
3.5 ± 0.6
[1.7-6.2]
3.8 ± 0.7
[1.7-6.7]
0.001
Serum phosphous within the K-DOQI target (2.8-4.6 mg/dL) (%) 85.1 86.8 83.5 0.12
Corrected calcium (mg/dL; mean ± SD [range]) 9.3 ± 0.5
[7-11.8]
9.3 ± 0.5
[7.9-11.6]
9.3 ± 0.5
[7-11.8]
0.64
Serum calcium within the K-DOQI target (8.4-9.5 md/dL) (%) 57.6 57.5 57.6 0.99
Calcium-Phosphorus product (mg/dL, mean[SD] [Range] 35 ± 6
[14-65]
33 ± 6
[17-59]
36 ± 7
[14-65]
0.002
Percentage of patients with calcium levels below normal (< 8.4 mg/dl) 3.3 2.1 4.0 NS
Percentage of patients with phosphorus levels above normal 9.4 2.6 13.6 0.001
Calcium-Phosphorus product within the K-DOQI target (< 55 mg2/dL2) (%) 98.6 99.5 98.1 0.047
i-PTH (pg/mL; mean ± SD [range]) 145 ± 116
[0-1166]
121 ± 99
[0-468]
166 ± 125
[9-1166]
0.001
Serum i-PTH within the K-DOQI target (%) [35-70 pg/mL (stage 3) or 70-110 pg/mL (stage 4)] 24.4 28.7 20.7 0.003
Meeting all four parameters according to K-DOQI guidelines (%) 10.5 12.2 9.0 0.10
Treatment with vitamin D (ergocalciferol/calcitriol) (%) 15.0 10.6 18.9 0.001
Treatment with phosphate binders (%) 19.7 11.9 26.7 0.001
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worthy of comment that in our population the other
two formulas appear to discriminate better regarding
CVD than the MDRD formula.
The prevalence of CVD in stage 3 subjects older than
60 years in this Spanish cohort is similar than the 36.6%
reported in CKD stage 3 subjects also older than 60
years in the USA by the National Health and Nutrition
Examination Survey Study (NHANES) [20]. The preva-
lence of CVD in this Spanish cohort however, is higher
than that reported from Italy in a cohort of patients
managed by nephrologists in renal clinics (29.7%) [15].
In both studies from two Mediterranean countries
where the delivery of care for CKD has similarities in
terms of being provided by nephrologists relatively early
in the course of the disease and under the auspices of a
government funded system.
Among the traditional risk factors for CVD, current
smoking was reported in 9.6% of the cohort and 10.5
and 8.8% of CKD stages 3 and 4, respectively. This is a
prevalence of current smokers lower than that reported
in the CRIC study, where smokers represented 14% of
the total cohort [16]. Former smokers in our cohort
were 36.2%. Among other traditional risk factors for
CKD our patients were predominantly male and an
overwhelming majority had hypertension (92.7%) and
diabetes was present in 40.8% of the subjects. In the
CRIC study, male preponderance was also noted (54%)
but the data is not completely comparable because in
this study the goal was to have equal gender for study
selection purposes. Proteinuria was present in a majority
of patients (62%) and was significantly higher in stage 4
than stage 3 CKD (See below).
The presence of hypertension in our cohort was
almost universal (92.7%) without significant differences
between stages 3 and 4 CKD (Table 3). The K/DOQI
guideline recommended target of systolic < 130 and
diastolic < 80 mm Hg [21] was achieved in only 17%
of patients, less than that reported in the CRIC study
(53%). In terms of control of hypertension, our data is
only slightly better than the findings from a similar
CKD cohort from Italy where only 12% of patients
achieved BP of less than 130/80 mmHg [15]. It should
be noted that the target blood pressure of < 130/80
mmHg may need to be re-evaluated in view of the
recent findings that there were no significant differ-
ences in kidney disease progression between standard
and intensive blood pressure control in the AASK
study [22]. The mean systolic BP in our cohort was
141 ± 19 mm Hg and there were no significant differ-
ences between stages 3 and 4 CKD patients. As a
group, this blood pressure is similar to the standard
control-group in the AASK study. Nevertheless, when
we consider a blood pressure target of 140/90 mmHg,
40.8% of the patients were on target (45.9% in CKD
stage 3 vs 37.7% in CKD stage 4 (p = 0.007)). Although
there is some debate, many experts think that there is
little evidence among patients with CKD that a BP
goal of < 130/80 mmHg saves lives, saves kidneys or
reduces cardiovascular events [23]. Hypertension ther-
apy should be individualized using home BP monitor-
ing and the precise targets must await randomized
controlled trials [23].
A large percentage of patients were receiving an ACE
inhibitor (43.3%), an ARB (44.8%) or combined ACE
inhibitors and ARBs (10.8%). The use of these agents
was significantly higher in stage 3 than in stage 4 CKD
patients (81.9 vs. 72.4%). The percentage of CKD 4
patients receiving diuretics was higher in stage 4 than
stage 3 CKD patients. There were no other significant
differences between stage 3 and 4 CKD patients regard-
ing other anti hypertensive agents. Plasma potassium
was slightly but significantly higher in stage 4 than stage
3 CKD patients and as expected the percentage of
patients with hyperkalemia was higher in stage 4 than in
stage 3 CKD (17.1 and 9.8%, respectively p < 0.001).
The data in our study regarding proteinuria was simi-
lar to that reported in an Italian CKD cohort where the
mean protein excretion was 0.8 and 1.2 g/24 hrs in
stages 3 and 4, respectively. By contrast the degree of
proteinuria in CRIC study was much lower (0.17 g/24
hours). The most likely explanation for the lesser degree
of proteinuria may be related to the better BP control in
the CRIC study where over 50% of the patients had
achieved a BP < 130/80 mm Hg. Consistent with this
notion the recently published AASK study showed
improved control of proteinuria with intensive blood
pressure control [22].
The prevalence of anemia and its severity was higher
in CKD stage 4 than CKD stage 3 patients and a larger
proportion of CKD stage 4 than stage 3 patients were
receiving ESAs. In those receiving ESAs, there were no
differences in the mean weekly dose between stages 3
and 4 CKD (Table 5). Of note, the mean hemoglobin of
the cohort was relatively high (12.8 g/dL) and the
majority of the patients had hemoglobin greater than 11
g/dL (87.6%). Since only 25.5% of the patients in the
total cohort were receiving ESA therapy, the relatively
high hemoglobin of the group as a whole cannot be
attributed to overtreatment with these agents. As
expected the prevalence of anemia, defined arbitrarily as
Hb < 11 g/dL, increased as the estimated GFR declines
(Figure 3).
About one third of the patients were receiving iron
therapies, mostly in the form of oral iron supplements.
Transferrin saturation < 20% was documented in 26.3%
of the patients therefore, suggesting under treatment
with iron in two significant portions of patients. These
findings suggest that there is a need for further
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utilization and/or optimization of iron therapies in the
CKD patients.
We think that the information from our cohort has
implications for the management of CKD associated
anemia. The initiation of ESA and maintenance of its
use in these patients has been generally targeted accord-
ing to the K-DOQI guidelines [24]. In our cohort, the
mean hemoglobin was 10.3 g/dL during the initiation of
ESA therapy. The use of ESA has been under great scru-
tiny and a moving target [24-27]. There is now a need
to reevaluate the management of anemia in CKD and
the data from this study will be timely. Clearly, our find-
ings suggest that the lower targets for hemoglobin that
are currently being proposed are achievable with
reduced use of ESAs in many CKD stages 3 and 4
patients.
Regarding calcium-phosphorus and PTH levels, a sali-
ent finding is that only 28.7% of subjects with stage 3
and 20.7% of subjects with stage 4 had levels of PTH
within the recommended targets based on K-DOQI
guidelines [28-31]. On the other hand, the majority of
subjects had phosphorus levels within the K-DOQI
guidelines and this was also reflected in the Ca-P pro-
duct within the K-DOQI guidelines in the majority of
subjects with both stage 3 and 4 CKD. This was accom-
plished even though only 11.9 and 26.9% of the subjects
were receiving phosphate binders in CKD stages 3 and
4, respectively. This probably reflects that an increase in
serum phosphorus occurs with more advanced CKD.
There was also very low percentage of subjects receiving
vitamin D and its analogues and this explains that the
levels of PTH were not in the desired target in the
majority of patients with CKD stages 3 and 4. Therefore,
it is reasonable to conclude that the overall management
of secondary hyperparathyroidism in this cohort could
benefit from treatment with Vitamin D and its
analogues.
Conclusions
In summary, the baseline characteristics of the MER-
ENA cohort provide information regarding a high level
of cardiovascular morbidity in stages 3 and 4 CKD
patients with a gradual increase noted when stage 3 is
subdivided into stages 3a and 3b. The presence of
hypertension was almost universal in stages 3 and 4
CKD despite the use of more than 3 anti-hypertensive
agents including widespread use of RAS blockers. The
majority of patients had secondary hyperparathyroidism
despite reasonable control of calcium-phosphorus levels
suggesting a need for vitamin D based therapies. Finally,
a majority of the patients had hemoglobin levels greater
than 11 g/dL while the use of ESA was limited to about
25% of patients.
In conclusion, this study provides an overview of key
clinical parameters in patients with CKD Stages 3 and 4
where delivery or care was largely by nephrologists
working in a network of hospital-based clinics of the
Spanish National Healthcare System.
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